Trial Outcomes & Findings for A Translational Approach to Gitelman Syndrome (NCT NCT00822107)
NCT ID: NCT00822107
Last Updated: 2019-04-05
Results Overview
Change from baseline in fractional chloride excretion in response to a single dose of hydrochlorothiazide
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
8 participants
Primary outcome timeframe
6 hours
Results posted on
2019-04-05
Participant Flow
Participant milestones
| Measure |
Thiazide Response
Hydrochlorothiazide 50 mg will be administered by mouth once.
Hydrochlorothiazide: 50 mg one time
|
|---|---|
|
Overall Study
STARTED
|
5
|
|
Overall Study
COMPLETED
|
5
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Thiazide Response
n=5 Participants
Hydrochlorothiazide 50 mg will be administered by mouth once.
Hydrochlorothiazide: 50 mg one time
|
|---|---|
|
Age, Continuous
|
42 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
5 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 6 hoursChange from baseline in fractional chloride excretion in response to a single dose of hydrochlorothiazide
Outcome measures
| Measure |
Thiazide Response
n=5 Participants
Hydrochlorothiazide 50 mg will be administered by mouth once.
Hydrochlorothiazide: 50 mg one time
|
|---|---|
|
Chloriuretic Response to a Thiaizde
|
1.23 fractional chloride excretion
Standard Deviation 0.93
|
Adverse Events
Thiazide Response
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place